Clinical Effect of Modified Erchentang in the Treatment of Chronic Obstructive Pulmonary Disease with Phlegm-Dampness Lung Syndrome
Objective To explore the clinical effect of modified Erchentang in the treatment of patients with COPD and phlegm-dampness lung syndrome.Methods 80 patients with COPD and phlegm-dampness lung syndrome who were admitted to Gushi County People's Hospital from October 2022 to October 2023 were selected.They were divided into a research group(n=40)and a control group(n=40)according to the random number table method.The control group was treated with conventional Western medicine,and the research group was treated with modified Erchentang combined with conventional Western medicine.The clinical efficacy,TCM syndrome score,lung function indicators,and inflammatory factors of the two groups were compared.Results The effective rate of treatment in the research group(97.50%)was higher than that in the control group(80.00%),and the difference was statistically significant(P＜0.05).After treatment,the TCM syndrome scores of both groups were lower than before treatment,and the research group was lower than the control group,and the differences were statistically significant(P＜0.05).After treatment,the total lung capacity(TLC),forced expiratory volume in the first second(FEV1),vital capacity(FVC),residual volume(RV),and tidal volume(TV)of both groups were higher than before treatment,and the research group was higher than the control group,and the differences were statistically significant(P＜0.05).After treatment,the levels of interferon-γ(IFN-γ)and endothelin-1(ET-1)in both groups were lower than before treatment,and the research group was lower than the control group,and the differences were statistically significant(P＜0.05).Conclusion The treatment of COPD with phlegm-dampness lung syndrome using modified Erchentang can improve the clinical efficacy,improve TCM syndrome and lung function,and effectively reduce the level of inflammatory factors.
国家科技期刊平台
NSTL
万方数据
